Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Summary
Hims and Hers has reached a new partnership agreement with pharmaceutical company Lilly regarding GLP-1 medications. Following the announcement of this deal, the company's shares experienced an upward price movement in the market. Under the terms of the arrangement, Hims agreed to stop compounding these specific treatments going forward.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Source: Read the full story at MarketWatch.com - Top Stories
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.